Ytterbium Triflate Mediated Selective Deprotection of Acetates
作者:G. V. M. Sharma、A. Ilangovan
DOI:10.1055/s-1999-2975
日期:1999.12
Ytterbium triflate mediated selective deprotection of acetates in isopropyl alcohol at reflux temperature is reported. Unlike hafnium triflate, under the present reaction conditions aryl acetates also undergo deacetylation instead of Fries migration.
HYDROCRACKING CATALYST, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING HYDROXY COMPOUND USING SAID CATALYST
申请人:Yoshii Kiyotaka
公开号:US20140288335A1
公开(公告)日:2014-09-25
The present invention provides a hydrocracking catalyst obtainable by mixing a metal compound (A) including any one metal of Groups 3 to 11 of the Periodic Table, a compound (B) including at least one compound selected from the group consisting of a ruthenium oxide compound (B1) and a high-valence compound (B2) including any metal of Groups 8 to 11 of the Periodic Table, and a metal oxide (C) including a metal of Group 5, Group 6 or Group 7 of the Periodic Table, and conducting reduction treatment.
The present invention provides a production method of a multifunctional acrylate with a reduced tin content which includes adding an acid to a mixture containing an organotin compound and a multifunctional acrylate and distilling the mixture containing the acid.
[EN] PROCESS FOR THE PREPARATION OF CLARITHROMYCIN<br/>[FR] PROCEDE POUR PREPARER DE LA CLARITHROMYCINE
申请人:SANDOZ AG
公开号:WO2005090377A1
公开(公告)日:2005-09-29
The present invention relates to a process for the production of clarithromycin using solvents with a low toxic potential and water.
本发明涉及一种利用具有低毒性潜力的溶剂和水生产克拉霉素的方法。
[EN] AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMINOALKYLPYRIMIDINE AU TITRE D'ANTAGONISTES DU RÉCEPTEUR HISTAMINIQUE H4
申请人:PALAU PHARMA SA
公开号:WO2011076878A1
公开(公告)日:2011-06-30
Aminoalkyipyrimidine derivatives of formula (I), wherein the meaning of the different substituents are those indicated in the description. These compounds are useful as histamine H4 receptor antagonists.